$MLTX News

MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds

MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions

What's Going On with MoonLake Immunotherapeutics Stock on Thursday?

MoonLake: Downgrading To Hold As FDA Priority Review Decision Remains

MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says

MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $50 Price Target

MoonLake Immunotherapeutics Files Biologics License Application To FDA For Nanobody Sonelokimab To Treat Hidradenitis Suppurativa

MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy

HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $50

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

MoonLake Immunotherapeutics Reports Topline Results From Phase 3 IZAR-1 Trial Showing Sonelokimab Met All Week 16 Endpoints In Biologic‑Naïve Psoriatic Arthritis Patients

MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate

MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $45 Price Target

MoonLake Immunotherapeutics' CFO Sells 39K Shares

Leerink Partners Maintains Outperform on MoonLake, Raises Price Target to $29

MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa